关于 Dinaqor ag

关于公司

DiNAQOR is a gene therapy platform company that focuses on advancing novel solutions for patients suffering from heart disease. The company's novel and innovative gene therapy platform is focused on advancing treatments for patients affected by genetic cardiomyopathies, a disease of the heart muscle that can lead to heart failure. Its lead preclinical program, DiNA-001, is focused on the treatment of MYBPC3-linked cardiomyopathy. DiNAQOR was founded in 2019 and is headquartered in Pfäffikon, Switzerland.